Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, February 2005, p. 853-856, Vol. 49, No. 2
0066-4804/05/$08.00+0 doi:10.1128/AAC.49.2.853-856.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Samuel C. Woolwine,1
Jacques H. Grosset,1
Fayez M. Hamzeh,2,
and
William R. Bishai1*
Departments of Medicine,1 Pharmacology, Johns Hopkins School of Medicine, Baltimore, Maryland2
Received 21 May 2004/ Returned for modification 27 July 2004/ Accepted 27 September 2004
To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.
Present address: Department of Epidemiology, Bloomberg School of Public Health, Baltimore, MD 21287.
Present address: Roche Laboratories Inc., Nutley, NJ 07110-1199.
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |